Related Experiment Video
Updated: Aug 5, 2026
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Effect of a high-dose bioactive components formula on reducing common diseases in term neonates delivered by cesarean
Ke Chen1, Xi Zhang2, Haixia Chen3
1Department of Clinical Nutrition, Chengdu Women's & Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Insights
A new infant formula with probiotics, lactoferrin (LF), milk fat globule membrane (MFGM), and nucleotides is safe for cesarean-born neonates. While it did not reduce upper respiratory tract infections (URTIs), it showed potential in lowering risks for functional dyspepsia and eczema.
Area of Science:
- Neonatal Nutrition
- Pediatric Gastroenterology
- Immunology
Background:
- Cesarean delivery impacts neonatal immune development and disease risk.
- Standard infant formulas may not fully replicate breast milk benefits.
- Novel nutritional interventions are needed to support infant health.
Purpose of the Study:
- To evaluate a high-dose probiotic-LF-MFGM-nucleotide formula's effect on common neonatal diseases.
- To assess the formula's impact on growth and hemoglobin levels in cesarean-born neonates.
- To determine the safety and tolerability of the combined formula.
Main Methods:
- A 3-month, prospective, multicenter, randomized controlled trial involving 150 neonates.
- Comparison of an intervention group (IG) with the novel formula against a control group (CG) with standard formula and a breastfeeding control group (BCG).
- Primary outcome: Upper Respiratory Tract Infection (URTI) incidence. Secondary outcomes: other symptoms, anthropometrics, and hemoglobin (Hb) levels.
Main Results:
- No significant difference in URTI incidence among the three groups.
- The intervention group showed reduced risks for functional dyspepsia (RR=0.756) and eczema (RR=0.647) compared to the control group.
- Hemoglobin levels were significantly higher in both formula groups (IG and CG) compared to the breastfeeding group, with no significant difference between IG and CG.
Conclusions:
- The high-dose probiotic-LF-MFGM-nucleotide formula is safe for term neonates born via cesarean section.
- The formula did not significantly reduce URTI incidence but showed promising, preliminary results for reducing functional dyspepsia and eczema.
- Further large-scale studies are needed to confirm the exploratory findings on specific symptom reductions.
Objective:
To investigate the effects of a high-dose probiotic-lactoferrin (LF)-milk fat globule membrane (MFGM)-nucleotide combined formula on reducing the incidence risk of common diseases and related symptoms and improving growth and hemoglobin level in neonates born via cesarean section.
Methods:
This trial was a prospective, multicenter, open-label, randomized, controlled 3-month intervention study. A total of 150 eligible neonates were enrolled. All participants completed the full intervention and provided clinical data. All enrolled formula-feeding neonates were randomly assigned to either the intervention group (IG, n = 50) or the control group (CG, n = 50), and 50 exclusively breastfed neonates were assigned to the breastfeeding control group (BCG). The formula used in the IG contained 2 × 109 CFU/100 g probiotics, 200 mg/100 g LF, added MFGM, and 55 mg/100 g nucleotides. In contrast, neonates in the CG were fed a formula containing 45-50 mg/100 g LF and 30-35 mg/100 g nucleotides, without probiotic or MFGM fortification. The primary outcome was the frequency of upper respiratory tract infections (URTIs). Secondary outcomes included the incidence of other respiratory, gastrointestinal, and allergic symptoms and diseases, as well as infant anthropometric indicators (including length, weight and head circumference) and the hemoglobin (Hb) concentration.
Result:
The incidence of URTIs over the 3-month intervention showed no significant difference among the three groups [the incidences of URTIs in CG, IG, and BCG: 22% (11/50), 18% (9/50), and 14% (7/50), respectively, χ2 = 1.084, p = 0.582] according to both intention-to-treat (TT) and per protocol (PP) analyses [incidence of URTIs in CG, IG, and BCG: 22.9% (11/48), 19.6% (9/46), and 14.9% (7/47), respectively, χ2 = 0.680, p = 0.712]. After the 3-month intervention, compared with infants in the CG, infants in the IG showed a reduced risk ration (RR) for functional dyspepsia [RR = 0.756, 95% confidence interval (95% CI) = 0.587-0.974] and eczema (RR = 0.647, 95% CI = 0.449-0.933). Hb levels in the CG and IG were both significantly higher than those in the BCG (107.35 ± 9.26 vs. 105.99 ± 7.01 vs. 101.42 ± 7.07 g/L for CG, IG, and BCG, respectively; F = 9.629, p < 0.001), with no statistically significant difference between the CG and IG. No significant differences in anthropometric indicators were observed among the three groups (p > 0.05).
Conclusion:
This study found no adverse effects associated with 3-month supplementation of a high-dose probiotic-LF-MFGM-nucleotide combined formula, supporting its safety for term neonates delivered by cesarean section. The primary outcome, URTI incidence, did not differ significantly among groups. Exploratory analyses suggested lower risks of functional dyspepsia and eczema in the intervention group; however, these findings should be considered preliminary and require confirmation in larger adequately powered studies. The intervention was well tolerated and showed safety comparable to standard feeding practices.
